TD Cowen raised the firm’s price target on Procept BioRobotics to $59 from $50 and keeps an Outperform rating on the shares. The firm said they maintain their rating based on the attractive multiyear growth outlook for Aquablation.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on PRCT:
- PROCEPT BioRobotics Reports Fourth Quarter and Full Year 2023 Results
- PROCEPT BioRobotics to Present at the 44th Annual TD Cowen Health Care Conference in Boston
- Procept BioRobotics price target raised to $58 from $42 at Piper Sandler
- Procept BioRobotics price target raised to $47 from $44 at Wells Fargo
- PROCEPT BioRobotics® Announces Preliminary Fourth Quarter Revenue of $43.3 million to $43.6 million